FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, who have progressed on or are intolerant to crizotinib.
NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.
